SEC Form 4 · accession 0001553878-17-000012
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Akshay Vaishnaw
Officer — SVP, R&D
Period of report
May 15, 2017
Accepted (ET)
May 17, 2017 · 6:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 15, 2017 | M | 32,750 | $31.39 | A | 43,047 | D | |
| Common Stock | May 15, 2017 | S | 32,750 | $65.00 | D | 10,297 | D | |
| Common Stock | May 15, 2017 | M | 11,000 | $21.35 | A | 21,297 | D | |
| Common Stock | May 15, 2017 | S | 11,000 | $65.00 | D | 10,297 | D | |
| Common StockF2 | holding | — | — | — | 286 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $21.35 | May 15, 2017 | M | 11,000 | D | — | Dec 8, 2018 | Common Stock | 11,000 | 44,994 | D |
| Stock Option (Right to Buy)F3 | $31.39 | May 15, 2017 | M | 32,750 | D | — | Dec 11, 2017 | Common Stock | 32,750 | 0 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2017. 32,750 and 11,000 options exercised and sold by the reporting person were due to expire on December 11, 2017 and December 8, 2018, respectively.
- F2The reporting person owns 286 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F3The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.